{
  "story_id": "852fbfe41c678fa467bb3e3d61342b58",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-02T10:07:35.000Z",
  "content_hash": "135e67857188f184a14fe3a52cf8dc2d43d2b561ebd3a6fe470cfd9886ee210f",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "New Review Finds GLP-1 Drugs Cause Major Weight Loss in Non-Diabetics",
    "dek": "A systematic review confirms GLP-1 receptor agonists produce significant weight loss in adults without diabetes, with tirzepatide showing the greatest results.",
    "prose": "Across the studies, participants taking GLP-1 RAs lost significantly more weight than those receiving a placebo. [^1]\n\nResearchers from Jewish General Hospital and McGill University published an updated systematic review in Annals of Internal Medicine evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among adults with overweight or obesity without diabetes. [^2]\n\nA new study found that patients taking GLP-1 drugs at low starter doses lose weight, though significantly less than those on higher manufacturer-recommended doses. [^3]\n\nSome emerging treatments were associated with weight loss exceeding 20% of body weight. [^4]\n\nThe review analyzed findings from 38 randomized controlled trials, including 14 newly identified studies, comprising a total of 25,816 adults. [^5]\n\nBy comparison, the average weight loss at one year on recommended higher doses was 20.2% with tirzepatide and 13.7% with semaglutide in an earlier head-to-head trial. [^6]\n\nLow-dose tirzepatide was associated with higher rates of kidney injury after two years in 2.7% of patients versus 0.4% with semaglutide. [^7]",
    "cited": "[{\"statement\":\"Across the studies, participants taking GLP-1 RAs lost significantly more weight than those receiving a placebo.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T11:40:03.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"Researchers from Jewish General Hospital and McGill University published an updated systematic review in Annals of Internal Medicine evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among adults with overweight or obesity without diabetes.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T11:40:03.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"A new study found that patients taking GLP-1 drugs at low starter doses lose weight, though significantly less than those on higher manufacturer-recommended doses.\",\"source\":\"The Hindu\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T10:07:35.000Z\",\"publisher_count\":1,\"sources\":[\"The Hindu\"]},{\"statement\":\"Some emerging treatments were associated with weight loss exceeding 20% of body weight.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T11:40:03.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"The review analyzed findings from 38 randomized controlled trials, including 14 newly identified studies, comprising a total of 25,816 adults.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T11:40:03.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"]},{\"statement\":\"By comparison, the average weight loss at one year on recommended higher doses was 20.2% with tirzepatide and 13.7% with semaglutide in an earlier head-to-head trial.\",\"source\":\"The Hindu\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T10:07:35.000Z\",\"publisher_count\":1,\"sources\":[\"The Hindu\"]},{\"statement\":\"Low-dose tirzepatide was associated with higher rates of kidney injury after two years in 2.7% of patients versus 0.4% with semaglutide.\",\"source\":\"The Hindu\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T10:07:35.000Z\",\"publisher_count\":1,\"sources\":[\"The Hindu\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "eab7021aa4358549ef59973980d3f577",
      "thread_id": "8f885ef3e104bcd336acfdbc43510a2b",
      "thread_label": "Mounjaro",
      "novelty": "UPDATE",
      "content_hash": "80c40a6dea96588721ab3ccd5df2addcc116517c97ee813d66805e2b7b66f1ce",
      "last_published_at": "2026-09-02T10:07:35.000Z",
      "read_receipt": {
        "slice_hash": "6f69d013059537a87af2b87c922b212011d4fe7ee12036f9066de5c4cc30281c",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDJUMDk6NTM6MDUuMDAwMDAwWiIsImlkIjoiNTA2NzViODllMmUyZDU3ZGJhMzQzOWRiYTFlYmRkYmYiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDJUMTE6MDA6MjIuMDAwMDAwWiIsImlkIjoiM2RkNTFiYjNlY2NkMTFkMzc0ZmJjN2UyNWU0OTBhOWYiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12017721,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "y-CC-1scxAEM_nQQodB8JAFq-dwPb14ApmlmnG93xGLLF_uL8rplYgVGN6oy6mZzw1MUve5kLVLnYlxMxRVBDA",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-02T22:46:18.723Z"
  },
  "cited_facts": [
    {
      "statement": "Across the studies, participants taking GLP-1 RAs lost significantly more weight than those receiving a placebo.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T11:40:03.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "Researchers from Jewish General Hospital and McGill University published an updated systematic review in Annals of Internal Medicine evaluating the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among adults with overweight or obesity without diabetes.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T11:40:03.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "A new study found that patients taking GLP-1 drugs at low starter doses lose weight, though significantly less than those on higher manufacturer-recommended doses.",
      "source": "The Hindu",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T10:07:35.000Z",
      "publisher_count": 1,
      "sources": [
        "The Hindu"
      ]
    },
    {
      "statement": "Some emerging treatments were associated with weight loss exceeding 20% of body weight.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T11:40:03.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "The review analyzed findings from 38 randomized controlled trials, including 14 newly identified studies, comprising a total of 25,816 adults.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T11:40:03.000Z",
      "publisher_count": 1,
      "sources": [
        "Medical Xpress"
      ]
    },
    {
      "statement": "By comparison, the average weight loss at one year on recommended higher doses was 20.2% with tirzepatide and 13.7% with semaglutide in an earlier head-to-head trial.",
      "source": "The Hindu",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T10:07:35.000Z",
      "publisher_count": 1,
      "sources": [
        "The Hindu"
      ]
    },
    {
      "statement": "Low-dose tirzepatide was associated with higher rates of kidney injury after two years in 2.7% of patients versus 0.4% with semaglutide.",
      "source": "The Hindu",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-02T10:07:35.000Z",
      "publisher_count": 1,
      "sources": [
        "The Hindu"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}